GOVERNMENT AGENCIES EXAMINE HOW HEALTHCARE
IS CHALLENGING TRADITIONAL ANTITRUST MODELS
Colleen Carroll, Catherine Poirier, Arthur Chen
Our academic experts continue to be at the forefront of contributors shaping some of the country’s most important public policy discussions.
Recently, Rena Conti, associate research director of the Institute for Health System Innovation and Policy at Boston University, and Luba Greenwood, lecturer in Engineering Sciences at Harvard University, spoke on a webinar co-hosted by the United States Patent and Trademark Office (USPTO) and the United States Department of Justice (DOJ) on the role of intellectual property (IP) in promoting innovation and pro-competitive collaboration in the life sciences sector.
Featuring over 40 experts from both industry and academia across the healthcare, regulatory and pricing spaces, the webinar, Promoting Innovation in the Life Sciences Sector and Supporting Pro-Competitive Collaborations: The Role of Intellectual Property, covered the rapidly evolving collaborations between biotech and pharmaceutical companies, and how they may be vulnerable to anti-competitive effects and antitrust risks in the U.S.
Speaking on two separate panels, both Keystone experts highlighted the rapid changes within the life sciences sector in the U.S. Both also offered prompt and necessary suggestions for changes in governance to advance competition and promote innovation across the healthcare industry.